$127 Million

Revance Therapeutics

Follow-on Offering

Lead Left Bookrunner, December 2019

Revance Therapeutics
Revance Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical. It is engaged in the clinical development for RT002 injectable and is focusing on developing RT002 for the treatment of glabellar lines, cervical dystonia and plantar fasciitis